Thursday, December 8, 2022
3:00 PM-7:00 PM
Friday, December 9, 2022
7:00 AM-10:00 AM
7:00 AM-6:00 PM
9:00 AM-11:00 AM
9:00 AM-12:00 PM
11:00 AM-2:00 PM
A Conversation With the Myeloma Experts: Making Sense of the Evolving Treatment Landscape
Friday Satellite Symposia
Advances in the Treatment of T-Cell Lymphomas: A Forum for Data and Case Discussion
Friday Satellite Symposia
An Expert Discussion on Myelodysplastic Syndromes: Current and Future Personalized Management Approaches
Friday Satellite Symposia
Complement Clinical Cases: Navigating Care for Patients with aHUS, PNH, and HSCT-TMA
Friday Satellite Symposia
Practice-Changing Data in Relapsed/Refractory Diffuse Large B-Cell Lymphoma—Integrating New Treatments
Friday Satellite Symposia
Rapidly Evolving Paradigms in Multiple Myeloma: Applying Current Data in the Clinic
Friday Satellite Symposia
Understanding the Biology and Addressing the Management Challenges of Cytopenic Myelofibrosis
Friday Satellite Symposia
12:30 PM-5:00 PM
Trainee Activities and Services
1:00 PM-3:00 PM
2:00 PM-5:00 PM
Scientific Workshops
3:00 PM-6:00 PM
Aggressive B-Cell Lymphomas: Experts Discuss New Care Standards and Evolving Treatment Strategies
Friday Satellite Symposia
AL Amyloidosis: Advances in Early Diagnosis, Treatment Options, and Individualized Care
Friday Satellite Symposia
A Review of Next-Generation Therapeutics and Contemporary Management of Myelofibrosis
Friday Satellite Symposia
'D' is for Diagnosis: Deciphering Uncommon Hematologic Disorders Through the Eyes of a Detective
Friday Satellite Symposia
JAK Inhibitors in Myelofibrosis: Expert Insights on Cases in Personalizing Therapy
Friday Satellite Symposia
Let’s Talk About Sickle Cell Disease: Perspectives, Case Challenges, and Clinical Pearls
Friday Satellite Symposia
Let’s Talk: Community Perspectives on Acute Myeloid Leukemia and Myelodysplastic Syndrome
Friday Satellite Symposia
7:00 PM-10:00 PM
Medical Crossfire®: How Do We Apply the Latest Evidence on Novel Therapies to Prevent and Treat GvHD?
Friday Satellite Symposia
Transfusion-Related Iron Overload – Evidence-Based Approaches to Improve Chelation Outcomes
Friday Satellite Symposia
Saturday, December 10, 2022
7:00 AM-7:45 AM
7:00 AM-6:00 PM
8:00 AM-9:00 AM
CANCELLED: Sickle Cell Disease – Where do Gene Therapy and Hematopoietic Cell Transplantation Fit into the Future Landscape
How I Treat: Bringing Science to Clinical Dilemmas
Can We Move Toward a Precision Medicine Approach for the Treatment of Higher Risk Myelodysplastic Syndromes
How I Treat: Bringing Science to Clinical Dilemmas
ITP/TTP – and Other Scary Causes of Thrombocytopenia - Saturday
How I Treat: Bringing Science to Clinical Dilemmas
The Case for MRD Testing and the Relevance to Treatment Decisions and Outcomes in AML.
How I Treat: Bringing Science to Clinical Dilemmas
9:00 AM-9:30 AM
9:00 AM-1:00 PM
9:00 AM-7:30 PM
9:05 AM-9:15 AM
9:15 AM-9:25 AM
9:30 AM-10:45 AM
9:30 AM-11:00 AM
114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Novel Therapies
Oral and Poster Abstracts
602. Myeloid Oncogenesis: Basic: Therapeutic Targeting of Myeloid Malignancies
Oral and Poster Abstracts
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological I
Oral and Poster Abstracts
636. Myelodysplastic Syndromes—Basic and Translational: Clonal Trajectories and Novel Therapies
Oral and Poster Abstracts
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Targeted Doublet Combinations
Oral and Poster Abstracts
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational I
Oral and Poster Abstracts
731. Autologous Transplantation: Clinical and Epidemiological: Multiple Myeloma and CHIP
Oral and Poster Abstracts
801. Gene Therapies: Addressing Challenges & Opportunities in Pre-clinical Settings
Oral and Poster Abstracts
11:00 AM-12:30 PM
11:00 AM-5:00 PM
11:05 AM-11:15 AM
11:15 AM-11:45 AM
11:15 AM-12:15 PM
11:20 AM-11:30 AM
11:30 AM-12:30 PM
11:35 AM-11:45 AM
12:00 PM-1:30 PM
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Lymphoma
Oral and Poster Abstracts
905. Outcomes Research—Lymphoid Malignancies: Health Outcomes in Plasma Cell Disorders and Transplant
Oral and Poster Abstracts
12:30 PM-1:30 PM
1:00 PM-3:00 PM
1:30 PM-1:45 PM
1:30 PM-2:00 PM
1:35 PM-1:45 PM
1:45 PM-1:55 PM
2:00 PM-3:00 PM
2:00 PM-3:15 PM
2:00 PM-3:30 PM
114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Hydroxyurea Treatment
Oral and Poster Abstracts
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Targeting BH3, BTK, and CDK
Oral and Poster Abstracts
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological III
Oral and Poster Abstracts
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational II
Oral and Poster Abstracts
705. Cellular Immunotherapies: Novel Predictors of Response or Toxicity to Cellular Therapies
Oral and Poster Abstracts
3:30 PM-4:00 PM
3:35 PM-3:45 PM
3:45 PM-3:55 PM
4:00 PM-5:15 PM
4:00 PM-5:30 PM
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational III
Oral and Poster Abstracts
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities III
Oral and Poster Abstracts
723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence II
Oral and Poster Abstracts
4:00 PM-5:35 PM
5:30 PM-7:30 PM
113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Poster I
Oral and Poster Abstracts
114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Poster I
Oral and Poster Abstracts
203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster I
Oral and Poster Abstracts
301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster I
Oral and Poster Abstracts
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I
Oral and Poster Abstracts
322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster I
Oral and Poster Abstracts
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster I
Oral and Poster Abstracts
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster I
Oral and Poster Abstracts
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster I
Oral and Poster Abstracts
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I
Oral and Poster Abstracts
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I
Oral and Poster Abstracts
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster I
Oral and Poster Abstracts
624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster I
Oral and Poster Abstracts
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I
Oral and Poster Abstracts
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I
Oral and Poster Abstracts
652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I
Oral and Poster Abstracts
653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster I
Oral and Poster Abstracts
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster I
Oral and Poster Abstracts
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster I
Oral and Poster Abstracts
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster I
Oral and Poster Abstracts
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I
Oral and Poster Abstracts
723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster I
Oral and Poster Abstracts
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I
Oral and Poster Abstracts
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster I
Oral and Poster Abstracts
6:30 PM-8:00 PM
Promoting Minorities in Hematology Oral Presentations Jefferson Ballroom - Classical Hematology
Special-Interest Sessions
Promoting Minorities in Hematology Oral Presentations St. Charles Ballroom - Malignant Hematology
Special-Interest Sessions
Promoting Minorities in Hematology Oral Presentations St. James Ballroom - Outcomes/Health Services
Special-Interest Sessions
8:00 PM-9:00 PM
Sunday, December 11, 2022
7:00 AM-9:00 AM
7:00 AM-5:00 PM
7:30 AM-9:30 AM
8:00 AM-9:00 AM
CANCELLED - vWD and Other Bleeding Disorders – Diagnostic Pitfalls and Special Situations
How I Treat: Bringing Science to Clinical Dilemmas
Thrombosis and Anticoagulation – Duration of Therapy, Thrombophilia - Sunday
How I Treat: Bringing Science to Clinical Dilemmas
Too Many Mast Cells and Eosinophils – How to Exclude (or Treat) Neoplastic Causes.
How I Treat: Bringing Science to Clinical Dilemmas
9:00 AM-9:30 AM
9:00 AM-8:00 PM
9:05 AM-9:15 AM
9:15 AM-9:25 AM
9:30 AM-10:45 AM
9:30 AM-11:00 AM
503. Clonal Hematopoiesis, Aging and Inflammation: Insights from Animal Models
Oral and Poster Abstracts
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: From Biology to Therapeutics
Oral and Poster Abstracts
731. Autologous Transplantation: Clinical and Epidemiological: Lymphoma, AML, and Multiple Sclerosis
Oral and Poster Abstracts
904. Outcomes Research—Non-Malignant Conditions: Classical Hematology: From Horses to Zebras
Oral and Poster Abstracts
9:30 AM-11:05 AM
10:00 AM-5:00 PM
11:00 AM-12:30 PM
11:05 AM-11:15 AM
11:15 AM-11:45 AM
11:15 AM-12:00 PM
11:15 AM-12:15 PM
Trainee Didactic Session: Writing a Good CV, Portfolio, and Biosketch
Trainee Activities and Services
11:15 AM-12:30 PM
ASH Practice Partnership Lunch - A Return to the Classics: The Need for Classical Hematology
Special-Interest Sessions
11:20 AM-11:30 AM
11:30 AM-12:30 PM
11:35 AM-11:45 AM
12:00 PM-1:30 PM
506. Bone Marrow Microenvironment: Contribution of Immune Signaling to the Microenvironment
Oral and Poster Abstracts
602. Myeloid Oncogenesis: Basic: Epigenetics and Transcriptional Regulation
Oral and Poster Abstracts
621. Lymphomas: Translational—Molecular and Genetic: ctDNA and Prognostication
Oral and Poster Abstracts
904. Outcomes Research—Non-Malignant Conditions: Sickle Cell Disease Therapies & Outcomes
Oral and Poster Abstracts
12:30 PM-12:59 PM
12:30 PM-1:30 PM
1:30 PM-2:00 PM
2:00 PM-4:00 PM
4:00 PM-4:15 PM
4:00 PM-4:30 PM
4:05 PM-4:15 PM
4:15 PM-4:25 PM
4:30 PM-5:45 PM
4:30 PM-6:00 PM
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological IV
Oral and Poster Abstracts
641. Chronic Lymphocytic Leukemias: Basic and Translational: Pathogenesis and Transformation
Oral and Poster Abstracts
705. Cellular Immunotherapies: Results from CD19-Directed CAR T in treating Aggressive B-cell Lymphomas
Oral and Poster Abstracts
4:30 PM-6:30 PM
6:00 PM-8:00 PM
113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Poster II
Oral and Poster Abstracts
114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Poster II
Oral and Poster Abstracts
203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II
Oral and Poster Abstracts
301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster II
Oral and Poster Abstracts
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster II
Oral and Poster Abstracts
322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster II
Oral and Poster Abstracts
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II
Oral and Poster Abstracts
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster II
Oral and Poster Abstracts
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster II
Oral and Poster Abstracts
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II
Oral and Poster Abstracts
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II
Oral and Poster Abstracts
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster II
Oral and Poster Abstracts
624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster II
Oral and Poster Abstracts
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II
Oral and Poster Abstracts
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II
Oral and Poster Abstracts
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II
Oral and Poster Abstracts
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II
Oral and Poster Abstracts
652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II
Oral and Poster Abstracts
653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster II
Oral and Poster Abstracts
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II
Oral and Poster Abstracts
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster II
Oral and Poster Abstracts
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster II
Oral and Poster Abstracts
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster II
Oral and Poster Abstracts
723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster II
Oral and Poster Abstracts
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II
Oral and Poster Abstracts
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster II
Oral and Poster Abstracts
Monday, December 12, 2022
7:00 AM-7:45 AM
7:00 AM-5:00 PM
7:30 AM-9:00 AM
8:00 AM-9:00 AM
9:00 AM-10:00 AM
9:00 AM-8:00 PM
10:00 AM-10:30 AM
10:00 AM-2:00 PM
10:05 AM-10:15 AM
10:15 AM-10:25 AM
10:15 AM-10:30 AM
10:30 AM-11:45 AM
10:30 AM-12:00 PM
114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Organ Function
Oral and Poster Abstracts
621. Lymphomas: Translational—Molecular and Genetic: Genomic Characterization
Oral and Poster Abstracts
626. Aggressive Lymphomas: Prospective Therapeutic Trials: Frontline Treatment of Large B-cell Lymphoma
Oral and Poster Abstracts
641. Chronic Lymphocytic Leukemias: Basic and Translational: Novel Therapies and Biomarkers
Oral and Poster Abstracts
705. Cellular Immunotherapies: Real World Outcomes and Special Populations Treated with Cellular Therapy
Oral and Poster Abstracts
723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence I
Oral and Poster Abstracts
801. Gene Therapies: Advances in Clinical Gene Therapy for Hematological Disorders
Oral and Poster Abstracts
12:00 PM-1:30 PM
12:05 PM-12:15 PM
12:15 PM-12:45 PM
12:15 PM-1:00 PM
12:15 PM-1:15 PM
12:20 PM-12:30 PM
Amplify Your Heart Brain for Improved Cognitive Function and Emotional Stability
ASH Wellness Studio
12:35 PM-12:45 PM
1:00 PM-1:30 PM
1:30 PM-2:30 PM
2:30 PM-2:45 PM
2:30 PM-3:00 PM
2:35 PM-2:45 PM
2:45 PM-4:00 PM
2:45 PM-4:15 PM
621. Lymphomas: Translational—Molecular and Genetic: Functional Genomics and Biology
Oral and Poster Abstracts
627. Aggressive Lymphomas: Clinical and Epidemiological: Predictors of Outcome
Oral and Poster Abstracts
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities II
Oral and Poster Abstracts
902. Health Services and Quality—Lymphoid Malignancies: Real World Consequences and Cost of Care
Oral and Poster Abstracts
904. Outcomes Research—Non-Malignant Conditions: Sickle Cell Care Across the Lifespan
Oral and Poster Abstracts
905. Outcomes Research—Lymphoid Malignancies: Outcomes in Childhood Leukemia/Lymphoma
Oral and Poster Abstracts
4:30 PM-5:45 PM
4:30 PM-6:00 PM
503. Clonal Hematopoiesis, Aging and Inflammation: Insights from Human Cohorts And Biosamples
Oral and Poster Abstracts
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutics
Oral and Poster Abstracts
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological II
Oral and Poster Abstracts
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Drugs in Development and COVID-19
Oral and Poster Abstracts
652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Disease Monitoring
Oral and Poster Abstracts
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities I
Oral and Poster Abstracts
905. Outcomes Research—Lymphoid Malignancies: Health Outcomes in CAR T and Stem Cell Transplantation
Oral and Poster Abstracts
ASH ISTH NHF WFH Guidelines on VWD: Impact on Patients, Policy, and Allied Health Professionals
Special-Interest Sessions
Driving Real-World Evidence for Hematologic Malignancy Research – A Joint ASH RC and EU HARMONY Session
Special-Interest Sessions
4:30 PM-6:05 PM
6:00 PM-8:00 PM
ASH and the ASH Research Collaborative: Advancing Progress in Sickle Cell Disease Update and Reception
Special-Interest Sessions
113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Poster III
Oral and Poster Abstracts
114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Poster III
Oral and Poster Abstracts
203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III
Oral and Poster Abstracts
301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster III
Oral and Poster Abstracts
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster III
Oral and Poster Abstracts
322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster III
Oral and Poster Abstracts
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster III
Oral and Poster Abstracts
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster III
Oral and Poster Abstracts
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster III
Oral and Poster Abstracts
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III
Oral and Poster Abstracts
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III
Oral and Poster Abstracts
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III
Oral and Poster Abstracts
624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster III
Oral and Poster Abstracts
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III
Oral and Poster Abstracts
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III
Oral and Poster Abstracts
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III
Oral and Poster Abstracts
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III
Oral and Poster Abstracts
652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III
Oral and Poster Abstracts
653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster III
Oral and Poster Abstracts
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster III
Oral and Poster Abstracts
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster III
Oral and Poster Abstracts
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster III
Oral and Poster Abstracts
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster III
Oral and Poster Abstracts
723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster III
Oral and Poster Abstracts
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III
Oral and Poster Abstracts
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster III
Oral and Poster Abstracts
6:30 PM-7:30 PM
Hemostasis and Thrombosis Community Networking Reception (for in-person participants)
Special-Interest Sessions